Literature DB >> 32638131

Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus.

Dai Shimizu1, Masahiko Koike2, Mitsuro Kanda2, Fuminori Sonohara2, Norifumi Hattori2, Masamichi Hayashi2, Chie Tanaka2, Suguru Yamada2, Yasuhiro Kodera2.   

Abstract

PURPOSE: We evaluated the efficacy of the long-term follow-up of patients who underwent radical esophagectomy for esophageal squamous cell carcinoma (ESCC) to screen for recurrence and new primary malignancies.
METHODS: We retrospectively collected 448 ESCC patients who underwent radical esophagectomy. Esophagogastroduodenoscopy, computed tomography, a stool test and the assessment of the serum concentration of squamous cell carcinoma antigen and carcinoembryonic antigen were performed annually, even over 5 years after esophagectomy. The incidence of ESCC recurrence and new primary malignancies was investigated.
RESULTS: We enrolled 222 patients who survived at least 5 years after esophagectomy. A total of 104 new primary malignancies occurred in 82 patients (36.9%) after esophagectomy. Twenty-one malignancies were in the head and neck region, 14 in the residual esophagus, 13 in the prostate and 11 in the gastric tube and lung. Patients who developed new primary malignancies after esophagectomy had a significantly higher Brinkman index than those without new malignancies. An endoscopic approach successfully treated 92.9% of carcinomas in the residual esophagus, 90.9% of cancers in the gastric tube and 42.9% of carcinomas in the head and neck region.
CONCLUSION: The incidence of new primary malignancies was higher than the age-standardized incidence. Long-term follow-up and systemic screening may increase the probability of an early diagnosis and subsequent low-invasive treatment.

Entities:  

Keywords:  Esophageal squamous cell carcinoma; Field cancerization; Multiple malignancy; Postoperative surveillance

Mesh:

Substances:

Year:  2020        PMID: 32638131     DOI: 10.1007/s00595-020-02072-w

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  26 in total

1.  Patterns of surveillance following curative intent therapy for gastroesophageal cancer.

Authors:  Renata D Peixoto; Howard J Lim; Haerin Kim; Ahmad Abdullah; Winson Y Cheung
Journal:  J Gastrointest Cancer       Date:  2014-09

2.  Risk Prediction of Postoperative Pneumonia After Subtotal Esophagectomy Based on Preoperative Serum Cholinesterase Concentrations.

Authors:  Mitsuro Kanda; Masahiko Koike; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Suguru Yamada; Kenji Omae; Yasuhiro Kodera
Journal:  Ann Surg Oncol       Date:  2019-06-13       Impact factor: 5.344

3.  Global trends in esophageal cancer.

Authors:  Gautam K Malhotra; Ujwal Yanala; Advaitaa Ravipati; Matthew Follet; M Vijayakumar; Chandrakanth Are
Journal:  J Surg Oncol       Date:  2017-03-20       Impact factor: 3.454

Review 4.  Oesophageal cancer.

Authors:  Jesper Lagergren; Elizabeth Smyth; David Cunningham; Pernilla Lagergren
Journal:  Lancet       Date:  2017-06-22       Impact factor: 79.321

5.  Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.

Authors:  Ken Kato; Takako Eguchi Nakajima; Yoshinori Ito; Chikatoshi Katada; Hiromichi Ishiyama; Shin-ya Tokunaga; Masahiro Tanaka; Shuichi Hironaka; Takayuki Hashimoto; Takashi Ura; Takeshi Kodaira; Ken-ichi Yoshimura
Journal:  Jpn J Clin Oncol       Date:  2013-04-12       Impact factor: 3.019

6.  Cost comparison study of two different follow-up protocols after surgery for oesophageal cancer.

Authors:  Suzanne Polinder; Els M L Verschuur; Peter D Siersema; Ernst J Kuipers; Ewout W Steyerberg
Journal:  Eur J Cancer       Date:  2009-04-22       Impact factor: 9.162

7.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Morihito Okada; Chen-Yuan Lin; Keisho Chin; Shigenori Kadowaki; Myung-Ju Ahn; Yasuo Hamamoto; Yuichiro Doki; Chueh-Chuan Yen; Yutaro Kubota; Sung-Bae Kim; Chih-Hung Hsu; Eva Holtved; Ioannis Xynos; Mamoru Kodani; Yuko Kitagawa
Journal:  Lancet Oncol       Date:  2019-09-30       Impact factor: 41.316

8.  Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.

Authors:  Tomoya Yokota; Ken Kato; Yasuo Hamamoto; Yasuhiro Tsubosa; Hirofumi Ogawa; Yoshinori Ito; Hiroki Hara; Takashi Ura; Takashi Kojima; Keisho Chin; Shuichi Hironaka; Takayuki Kii; Yasushi Kojima; Yasunori Akutsu; Hisayuki Matsushita; Kentaro Kawakami; Keita Mori; Yushi Nagai; Chika Asami; Yuko Kitagawa
Journal:  Br J Cancer       Date:  2016-11-03       Impact factor: 7.640

9.  Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble.

Authors:  Vasilis Kontis; James E Bennett; Colin D Mathers; Guangquan Li; Kyle Foreman; Majid Ezzati
Journal:  Lancet       Date:  2017-02-22       Impact factor: 79.321

10.  Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis.

Authors:  Mitsuro Kanda; Masahiko Koike; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Suguru Yamada; Goro Nakayama; Kenji Omae; Yasuhiro Kodera
Journal:  BMC Surg       Date:  2019-10-15       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.